Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668066 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT04668066 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 121 participants.
The verdict
NCT04668066, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07242813 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms.
Interventions
- DRUG Placebo
- DRUG PF-07242813
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668066
The ClinicalTrials.gov registry entry for NCT04668066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04668066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668066 about?
NCT04668066 is a clinical study titled "Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis". This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional...
What is the current status of trial NCT04668066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2020-12-10. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT04668066?
The interventions under investigation include: Placebo (DRUG), PF-07242813 (DRUG).
Who is sponsoring clinical trial NCT04668066?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.